Literature DB >> 26723943

[Nodular regenerative hyperplasia associated with common variable immunodeficiency and other comorbidities].

Rafael León1, Rosario Sánchez-Martínez2, José M Palazón3, Artemio Payá4, José M Ramos5, Héctor Pinargote2.   

Abstract

BACKGROUND AND
OBJECTIVE: Currently, there are not many data on the evolution of nodular regenerative hyperplasia (NRH) associated or not with underlying diseases and in particular that associated with common variable inmunodeficiency (CVID). Twenty cases of NRH are presented, and the differences between the cases associated with CVID and those related to other diseases are analysed.
METHODS: Retrospective and descriptive study over a period of 14 years.
RESULTS: Twelve out of the 20 patients were men; the median age was 51 years. CVID was the main illness associated with NRH. In patients with CVID and NRH, gastrointestinal haemorrhage was more common, all the patients had high gamma glutamyl transferase and alkaline phosphatase and none had altered albumin and bilirubin levels compared to the patients without CVID. On follow-up, 50% of patients with CVID (2/4) had died compared to 33.3% (5/15) without CVID.
CONCLUSIONS: NRH in patients with CVID seems to have more biochemical data of anicteric cholestasis and portal hypertension and could be associated with lower survival.
Copyright © 2015 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Common variable immunodeficiency; Hiperplasia nodular regenerativa; Hipertensión portal; Inmunodeficiencia común variable; Nodular regenerative hyperplasia; Portal hypertension

Mesh:

Year:  2015        PMID: 26723943     DOI: 10.1016/j.medcli.2015.11.008

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Patients with common variable immunodeficiency paradoxically have increased rates of autoimmune disorders.

Authors:  Ammu Thampi Susheela; Andrew Hale
Journal:  BMJ Case Rep       Date:  2017-10-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.